The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy
Author:
Tangen Catherine M.
Reference12 articles.
1. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H.(2006) APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 52:1089–95. 2. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS.; Free PSA Study Group. (2006) A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology. 67:762–8. 3. Martin BJ, Cheli CD, Sterling K, Ward M, Pollard S, Lifsey D, Mercante D, Martin L, Rayford W. (2006) Prostate specific antigen isoforms and human glandular kallikrein 2- which offers the best screening performance in a predominantly black population? ? J Urol. 175:104–7. 4. Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, Feng Z, Parnes HL, Coltman CA Jr. (2006) Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 98:529–34. 5. Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia MS, Goodman PH, Parnes H, Coltman CA. (2008) The performance of PSA for predicting prostate cancer is maintained after a prior negative biopsy. J Urol. 180:544–7.
|
|